Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Recruiting 2Completed 2Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Pancreatic Neoplasms 1Esophageal Neoplasms 1Anophthalmia with pulmonary hypoplasia 1

Interventions

Bevacizumab 47lenvatinib 36atezolizumab 36durvalumab 28tremelimumab 23sintilimab 19Nivolumab 18pembrolizumab 14Radiosurgery 13tislelizumab 11Specimen Handling 10Ipilimumab 10camrelizumab 8apatinib 8Oxaliplatin 8Immune Checkpoint Inhibitors 8Fluorouracil 8Cyclophosphamide 8Blood Specimen Collection 8regorafenib 7cabozantinib 7fludarabine 6Sorafenib 6Radiotherapy 6Magnetic Resonance Spectroscopy 6Leucovorin 6donafenib 5Surgical Procedures, Operative 5Injections 5Immunoglobulin G 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Hepatocellular × budigalimab × Clear all
NCT06109272 2025-08-15

LIVIGNO-2

AbbVie

Phase 2/3 Recruiting
660 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06487559 2025-03-04

A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)

AbbVie

Phase 1 Recruiting
20 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡